{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:10:13Z","timestamp":1760235013403,"version":"build-2065373602"},"reference-count":84,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Societe Francaise de Medecine Predictive et Personnalisee (SFMPP)","award":["2020-01"],"award-info":[{"award-number":["2020-01"]}]},{"name":"Entrepreneurs &amp; go","award":["2020-02"],"award-info":[{"award-number":["2020-02"]}]},{"name":"Association Les Sapins de Noel des Cr\u00e9ateurs","award":["2019-01"],"award-info":[{"award-number":["2019-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>According to clinical guidelines, the occurrence of very early-onset breast cancer (VEO-BC) (diagnosed \u2264 age 30 years) or VEO ovarian cancer (VEO-OC) (diagnosed \u2264 age 40 years) in families with BRCA1 or BRCA2 mutation (BRCAm) prompts advancing the age of risk-reducing strategies in relatives. This study aimed to assess the relation between the occurrence of VEO-BC or VEO-OC in families with BRCAm and age at BC or OC diagnosis in relatives. We conducted a retrospective multicenter study of 448 consecutive families with BRCAm from 2003 to 2018. Mean age and 5-year\u2013span distribution of age at BC or OC in relatives were compared in families with or without VEO-BC or VEO-OC. Conditional probability calculation and Cochran\u2013Mantel\u2013Haenszel chi-square tests were used to investigate early-onset cancer occurrence in relatives of VEO-BC and VEO-OC cases. Overall, 15% (19\/245) of families with BRCA1m and 9% (19\/203) with BRCA2m featured at least one case of VEO-BC; 8% (37\/245) and 2% (2\/203) featured at least one case of VEO-OC, respectively. The cumulative prevalence of VEO-BC was 5.1% (95% CI 3.6\u20136.6) and 2.5% (95% CI 1.4\u20133.6) for families with BRCA1m and BRCA2m, respectively. The distribution of age and mean age at BC diagnosis in relatives did not differ by occurrence of VEO-BC for families with BRCA1m or BRCA2m. Conditional probability calculations did not show an increase of early-onset BC in VEO-BC families with BRCA1m or BRCA2m. Conversely, the probability of VEO-BC was not increased in families with early-onset BC. VEO-BC or VEO-OC occurrence may not be related to young age at BC or OC onset in relatives in families with BRCAm. This finding\u2014together with a relatively high VEO-BC risk for women with BRCAm\u2014advocates for MRI breast screening from age 25 regardless of family history.<\/jats:p>","DOI":"10.3390\/genes12071100","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T11:26:10Z","timestamp":1626780370000},"page":"1100","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families"],"prefix":"10.3390","volume":"12","author":[{"given":"Marion","family":"Imbert-Bouteille","sequence":"first","affiliation":[{"name":"Cancer Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Corsini","sequence":"additional","affiliation":[{"name":"Cancer Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Picot","sequence":"additional","affiliation":[{"name":"Clinical Research and Epidemiology Unit, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Mizrahy","sequence":"additional","affiliation":[{"name":"Cancer Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"},{"name":"Medecine Department, School Medecine, Medecine College, Federal University of Juiz de Fora, Juiz de Fora 36036-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Akouete","sequence":"additional","affiliation":[{"name":"Clinical Research and Epidemiology Unit, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Huguet","sequence":"additional","affiliation":[{"name":"Clinical Research and Epidemiology Unit, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-1978","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Thomas","sequence":"additional","affiliation":[{"name":"CNRS, Laboratory CREEC, MIVEGEC, IRD, 34394 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-6287","authenticated-orcid":false,"given":"David","family":"Genevi\u00e8ve","sequence":"additional","affiliation":[{"name":"Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de M\u00e9decine Pr\u00e9dictive et Personnalis\u00e9e, SFMPP, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Taourel","sequence":"additional","affiliation":[{"name":"Imagerie m\u00e9dicale, Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ychou","sequence":"additional","affiliation":[{"name":"Department of Oncology, ICM-Val d\u2019Aurelle Cancer Center, 34298 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Galibert","sequence":"additional","affiliation":[{"name":"Cancer Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Rideau","sequence":"additional","affiliation":[{"name":"Cancer Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Baudry","sequence":"additional","affiliation":[{"name":"Cancer Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Kogut Kubiak","sequence":"additional","affiliation":[{"name":"Cancer Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Coupier","sequence":"additional","affiliation":[{"name":"Cancer Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Hobeika","sequence":"additional","affiliation":[{"name":"Cancer Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"},{"name":"Genetics Department, French Hospital du Levant, Beirut 50-226, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette","family":"Macary","sequence":"additional","affiliation":[{"name":"Cancer Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"},{"name":"Genetics Department, French Hospital du Levant, Beirut 50-226, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Toledano","sequence":"additional","affiliation":[{"name":"Oncology Department, Clinique Hartmann, 92309 Levallois, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0293-6158","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Solassol","sequence":"additional","affiliation":[{"name":"Department of Pathology and Onco-Biology, IRCM, ICM, CHU Montpellier, INSERM, Universit\u00e9 Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Maalouf","sequence":"additional","affiliation":[{"name":"Genetics Department, French Hospital du Levant, Beirut 50-226, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Daures","sequence":"additional","affiliation":[{"name":"Biostatistics Department, University of Montpellier I, CHU Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8315-4715","authenticated-orcid":false,"given":"Pascal","family":"Pujol","sequence":"additional","affiliation":[{"name":"Cancer Genetics Department, CHU Montpellier, Universit\u00e9 Montpellier, 34295 Montpellier, France"},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de M\u00e9decine Pr\u00e9dictive et Personnalis\u00e9e, SFMPP, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ng0396-333","article-title":"The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds","volume":"12","author":"Tavtigian","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/jmg.31.12.944","article-title":"Genetic epidemiology of early onset breast cancer","volume":"31","author":"Eccles","year":"1994","journal-title":"J. Med. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1086\/302671","article-title":"The genetic epidemiology of early-onset epithelial ovarian cancer: A population-based study","volume":"65","author":"Stratton","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"ref_7","first-page":"265","article-title":"Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium","volume":"56","author":"Easton","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.femme.2018.01.004","article-title":"Suivi des patientes porteuses d\u2019une mutation des g\u00e8nes BRCA1 et 2: Recommandations de l\u2019InCa 2017","volume":"28","year":"2018","journal-title":"Imagerie de la Femme"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.6004\/jnccn.2014.0127","article-title":"Genetic\/familial high-risk assessment: Breast and ovarian, version 1.2014","volume":"12","author":"Daly","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","article-title":"Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening","volume":"27","author":"Cardoso","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_15","unstructured":"(2019). Tools and Resources. Familial Breast Cancer: Classification, Care and Managing Breast Cancer and Related Risks in People with a Family History of Breast Cancer, National Institute for Health and Care Excellence. Guidance, NICE."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/CEJ.0000000000000624","article-title":"Hereditary Breast Cancer: Translation into Clinical Practice of Recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology Recommendations","volume":"30","author":"Corso","year":"2021","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jnci\/djq443","article-title":"Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations","volume":"102","author":"Metcalfe","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10549-015-3596-8","article-title":"Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?","volume":"154","author":"Semple","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ijc.28014","article-title":"Optimal age to start preventive measures in women with BRCA1\/2 mutations or high familial breast cancer risk","volume":"133","author":"Lingsma","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1399-0004.2009.01328.x","article-title":"Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?","volume":"77","author":"Panchal","year":"2010","journal-title":"Clin. Genet."},{"key":"ref_22","unstructured":"Cooper, J.M. (2010). Factors Associated with Early Versus Late Development of Breast and Ovarian Cancer in BRCA1 and BRCA2 Positive Women, The Texas Medical Center Library."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/00016340902807207","article-title":"Risk of ovarian cancer in women with first-degree relatives with cancer","volume":"88","author":"Soegaard","year":"2009","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1471-0528.1998.tb10148.x","article-title":"A systematic review and meta-analysis of family history and risk of ovarian cancer","volume":"105","author":"Stratton","year":"1998","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B","article-title":"Family history and the risk of breast cancer: A systematic review and meta-analysis","volume":"71","author":"Pharoah","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.2007.55-a","article-title":"Variation of Breast Cancer Risk Among BRCA1\/2 Carriers","volume":"299","author":"Begg","year":"2008","journal-title":"JAMA"},{"key":"ref_27","first-page":"329","article-title":"Variation in BRCA1 cancer risks by mutation position","volume":"11","author":"Thompson","year":"2002","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00006254-200301000-00016","article-title":"Cancer Incidence in BRCA1 Mutation Carriers","volume":"58","author":"Thompson","year":"2003","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fonc.2018.00490","article-title":"GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers","volume":"8","author":"Lesueur","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-013-2669-9","article-title":"Lack of referral for genetic counseling and testing in BRCA1\/2 and Lynch syndromes: A nationwide study based on 240,134 consultations and 134,652 genetic tests","volume":"141","author":"Pujol","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/318181","article-title":"Variation in cancer risks, by mutation position, in BRCA2 mutation carriers","volume":"68","author":"Thompson","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Yoshida, R. (2020). Hereditary Breast and Ovarian Cancer (HBOC): Review of Its Molecular Characteristics, Screening, Treatment, and Prognosis. Breast Cancer.","DOI":"10.1007\/s12282-020-01148-2"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17","author":"Timms","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000455820","article-title":"Biological Subtypes of Triple-Negative Breast Cancer","volume":"12","author":"Hubalek","year":"2017","journal-title":"Breast Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc2054","article-title":"Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations","volume":"7","author":"Fackenthal","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/cge.12270","article-title":"Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: A meta-analysis","volume":"85","author":"Tun","year":"2014","journal-title":"Clin. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/1078-0432.CCR-15-0459","article-title":"Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study","volume":"22","author":"Podo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"vi23","DOI":"10.1093\/annonc\/mds191","article-title":"Imaging of triple-negative breast cancer","volume":"23","author":"Dogan","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0959-8049(09)70013-9","article-title":"Triple negative breast cancers: Clinical and prognostic implications","volume":"45","author":"Dawson","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: Clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijsu.2015.06.023","article-title":"The significance and the predictive factors of microscopic lymph node metastasis in patients with clinically node negative papillary thyroid cancer: A retrospective cohort study","volume":"20","author":"Noda","year":"2015","journal-title":"Int. J. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1200\/JCO.2014.56.6232","article-title":"Magnetic Resonance Imaging Improves Breast Screening Sensitivity in BRCA Mutation Carriers Age \u2265 50 Years: Evidence From an Individual Patient Data Meta-Analysis","volume":"33","author":"Phi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/bjc.2016.32","article-title":"Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: Individual patient data meta-analysis","volume":"114","author":"Phi","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2014.56.8626","article-title":"Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density","volume":"33","author":"Riedl","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Metcalfe, K., Eisen, A., Senter, L., Armel, S., Bordeleau, L., Meschino, W.S., Pal, T., Lynch, H.T., Tung, N.M., and Kwong, A. (2019). International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br. J. Cancer.","DOI":"10.1038\/s41416-019-0446-1"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ejhg.2010.241","article-title":"Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1\/2 mutations","volume":"19","author":"Mancini","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/bjc.2013.149","article-title":"Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness","volume":"108","author":"Vermeulen","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Pataky, R., Armstrong, L., Chia, S., Coldman, A.J., Kim-Sing, C., McGillivray, B., Scott, J., Wilson, C.M., and Peacock, S. (2013). Cost-effectiveness of MRI for breast cancer screening in BRCA1\/2 mutation carriers. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-339"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/gim.2017.255","article-title":"Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1\/2 mutation carriers: A systematic review","volume":"20","author":"Petelin","year":"2018","journal-title":"Genet. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s40618-016-0467-z","article-title":"Premature ovarian insufficiency: The context of long-term effects","volume":"39","author":"Czyzyk","year":"2016","journal-title":"J. Endocrinol. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Marchetti, C., De Felice, F., Palaia, I., Perniola, G., Musella, A., Musio, D., Muzii, L., Tombolini, V., and Panici, P.B. (2014). Risk-reducing salpingo-oophorectomy: A meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Women\u2019s Health, 14.","DOI":"10.1186\/s12905-014-0150-5"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of Risk Reduction Estimates Associated with Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00508-015-0880-x","article-title":"Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families","volume":"127","author":"Singer","year":"2015","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10689-014-9777-5","article-title":"Impact of BRCA1\/2 mutation on young women\u2019s 5-year parenthood rates: A prospective comparative study (GENEPSO-PS cohort)","volume":"14","author":"Mancini","year":"2015","journal-title":"Fam. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.fertnstert.2015.07.233","article-title":"Reproductive decision-making in patients diagnosed with BRCA mutations","volume":"104","author":"Chan","year":"2015","journal-title":"Fertil. Steril."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/humrep\/dex356","article-title":"Fertility preservation in women harboring deleterious BRCA mutations: Ready for prime time?","volume":"33","author":"Peccatori","year":"2018","journal-title":"Hum. Reprod."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/j.fertnstert.2013.07.1389","article-title":"BRCA mutation carriers: A new target population for fertility preservation consultation and treatment","volume":"100","author":"Kim","year":"2013","journal-title":"Fertil. Steril."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.fertnstert.2018.10.014","article-title":"BRCA carriers have similar reproductive potential at baseline to noncarriers: Comparisons in cancer and cancer-free cohorts undergoing fertility preservation","volume":"111","author":"Gunnala","year":"2019","journal-title":"Fertil. Steril."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2217\/fon-2017-0415","article-title":"Fertility preservation in BRCA-mutated women: When and how?","volume":"14","author":"Grynberg","year":"2018","journal-title":"Future Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"T69","DOI":"10.1530\/ERC-16-0277","article-title":"Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers","volume":"23","author":"Milne","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/sj.bjc.6605416","article-title":"Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1\/BRCA2 (CIMBA)","volume":"101","author":"Osorio","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3052","article-title":"Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1\/2","volume":"13","author":"Mulligan","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1093\/hmg\/ddr226","article-title":"Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers","volume":"20","author":"Antoniou","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"HBPP1674","DOI":"10.4172\/1948-5956.C1.061","article-title":"Genotype and phenotype correlation of breast cancer in BRCA carriers and non-carriers","volume":"07","author":"Bugrein","year":"2015","journal-title":"J. Cancer Sci. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Bujassoum, S.M., Bugrein, H.A., and Al Sulaiman, R. (2017). Genotype and Phenotype Correlation of Breast Cancer in BRCA Mutation Carriers and Non-Carriers. J. Cancer Sci. Ther., 9.","DOI":"10.4172\/1948-5956.1000442"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/1055-9965.EPI-14-0884","article-title":"Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1\/2 Carriers","volume":"24","author":"Lecarpentier","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2005.03.3126","article-title":"Effect of chest X-rays on the risk of breast cancer among BRCA1\/2 mutation carriers in the international BRCA1\/2 carrier cohort study: A report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators\u2019 Group","volume":"24","author":"Andrieu","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1038\/sj.onc.1209870","article-title":"Modifiers of risk of hereditary breast cancer","volume":"25","author":"Narod","year":"2006","journal-title":"Oncogene"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"dju091","DOI":"10.1093\/jnci\/dju091","article-title":"Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: Systematic review and meta-analysis","volume":"106","author":"Friebel","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","article-title":"Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes","volume":"104","author":"Mavaddat","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41436-020-0862-x","article-title":"Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants","volume":"22","author":"Barnes","year":"2020","journal-title":"Genet. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e208501","DOI":"10.1001\/jamanetworkopen.2020.8501","article-title":"Association of a Polygenic Risk Score with Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes","volume":"3","author":"Gallagher","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41591-020-0800-0","article-title":"Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers","volume":"26","author":"Mars","year":"2020","journal-title":"Nat. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s11606-009-1009-6","article-title":"Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: Early disagreements and low utilization","volume":"24","author":"Levy","year":"2009","journal-title":"J. Gen. Intern. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","article-title":"Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer","volume":"14","author":"George","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_81","unstructured":"(2019, May 11). U.S. Breast Cancer Statistics. Available online: https:\/\/www.breastcancer.org\/symptoms\/understand_bc\/statistics."},{"key":"ref_82","unstructured":"(2019, May 11). Institut National Du Cancer Epid\u00e9miologie des Cancers\u2014Les chiffres du Cancer en France. Available online: https:\/\/www.e-cancer.fr\/Professionnels-de-sante\/Les-chiffres-du-cancer-en-France\/Epidemiologie-des-cancers."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/ije\/dys049","article-title":"Classification of epidemiological study designs","volume":"41","author":"Pearce","year":"2012","journal-title":"Int. J. Epidemiol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kass, P.H. (2014). Modern Epidemiological Study Designs. Handbook of Epidemiology, Springer.","DOI":"10.1007\/978-0-387-09834-0_8"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/7\/1100\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:32:17Z","timestamp":1760164337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/7\/1100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":84,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["genes12071100"],"URL":"https:\/\/doi.org\/10.3390\/genes12071100","relation":{},"ISSN":["2073-4425"],"issn-type":[{"type":"electronic","value":"2073-4425"}],"subject":[],"published":{"date-parts":[[2021,7,20]]}}}